IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CRISCITIELLO, CARMEN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.557
NA - Nord America 4.324
AS - Asia 3.334
SA - Sud America 239
OC - Oceania 75
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 10
Totale 16.590
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.135
DE - Germania 3.751
GB - Regno Unito 1.967
CN - Cina 1.656
IT - Italia 1.052
SG - Singapore 622
SE - Svezia 536
RU - Federazione Russa 270
IN - India 214
JP - Giappone 206
IE - Irlanda 198
FR - Francia 173
BR - Brasile 172
CA - Canada 144
HK - Hong Kong 120
ID - Indonesia 112
ES - Italia 105
NL - Olanda 93
KR - Corea 74
TR - Turchia 71
AU - Australia 65
TW - Taiwan 64
VN - Vietnam 64
CH - Svizzera 59
FI - Finlandia 56
AT - Austria 54
DK - Danimarca 37
MX - Messico 37
BE - Belgio 32
TH - Thailandia 24
GR - Grecia 23
AR - Argentina 22
PL - Polonia 22
NO - Norvegia 20
RO - Romania 20
PH - Filippine 19
UA - Ucraina 17
PT - Portogallo 16
IR - Iran 14
CO - Colombia 13
CZ - Repubblica Ceca 11
EG - Egitto 10
NZ - Nuova Zelanda 10
AE - Emirati Arabi Uniti 9
EC - Ecuador 9
CL - Cile 8
MA - Marocco 7
TN - Tunisia 7
AM - Armenia 6
AP - ???statistics.table.value.countryCode.AP??? 6
DZ - Algeria 6
JO - Giordania 6
KE - Kenya 6
LT - Lituania 6
PK - Pakistan 6
SK - Slovacchia (Repubblica Slovacca) 6
ZA - Sudafrica 6
BD - Bangladesh 5
BY - Bielorussia 5
EU - Europa 5
HR - Croazia 5
HU - Ungheria 5
KG - Kirghizistan 5
MY - Malesia 5
PS - Palestinian Territory 5
CY - Cipro 4
PA - Panama 4
PE - Perù 4
SC - Seychelles 4
SI - Slovenia 4
UY - Uruguay 4
EE - Estonia 3
IL - Israele 3
LB - Libano 3
NG - Nigeria 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BO - Bolivia 2
CU - Cuba 2
GE - Georgia 2
IQ - Iraq 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
AL - Albania 1
AZ - Azerbaigian 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
GY - Guiana 1
HN - Honduras 1
IM - Isola di Man 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MO - Macao, regione amministrativa speciale della Cina 1
PY - Paraguay 1
QA - Qatar 1
RE - Reunion 1
Totale 16.587
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 3.408
Southend 1.823
Milan 461
Singapore 372
Chandler 337
Fairfield 313
Houston 298
Ashburn 278
Beijing 205
Dublin 194
Wilmington 191
Princeton 190
Council Bluffs 176
Santa Clara 141
Guangzhou 138
Nanjing 138
Shanghai 136
Woodbridge 127
Seattle 124
Redwood City 122
Cambridge 114
Jakarta 89
Ann Arbor 78
Bengaluru 66
Toronto 66
Dearborn 65
Des Moines 64
Shenyang 55
Hong Kong 54
Tokyo 49
Jinan 47
Hangzhou 46
New York 46
Phoenix 44
Rome 42
Boardman 39
San Diego 36
Helsinki 34
Istanbul 33
Hyderabad 32
Seoul 32
Zhengzhou 32
Vienna 31
London 30
São Paulo 30
Nuremberg 29
Changsha 27
Taipei 27
Berlin 26
Fuzhou 26
Sunnyvale 26
Hanover 25
Hebei 24
Grafing 23
Wuhan 23
Amsterdam 22
Silver Spring 22
Los Angeles 21
Madrid 20
Munich 20
Rho 20
Tianjin 20
Dong Ket 19
Pune 18
Barcelona 17
Boston 17
Turin 17
Nanchang 16
Redmond 16
Florence 15
Ottawa 15
Paris 14
Central District 13
Haikou 13
Naples 13
Jiaxing 12
Montréal 12
Sydney 12
Taiyuan 12
Chengdu 11
Kunming 11
Osaka 11
Padova 11
Philadelphia 11
Quanzhou 11
Zurich 11
Bangkok 10
Brussels 10
Moscow 10
Piscataway 10
The Dalles 10
Washington 10
Belo Horizonte 9
Buenos Aires 9
Fisciano 9
Fort Worth 9
Fremont 9
Groningen 9
Lappeenranta 9
Oklahoma City 9
Totale 11.287
Salva come PNG Salva come JPEG
Nome #
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 1.371
Global cancer control: responding to the growing burden, rising costs and inequalities in access 762
Entinostat for the treatment of breast cancer 753
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 718
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 554
Managing side effects of immune checkpoint inhibitors in breast cancer 296
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 250
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 247
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs 229
Expression of tumor-associated antigens in breast cancer subtypes 227
Antibody–drug conjugates in solid tumors: a look into novel targets 226
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 195
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology 186
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 178
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 164
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients : a Single-Institute Study 162
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 158
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 156
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 153
Tumour dormancy and clinical implications in breast cancer 152
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 149
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 142
Immune checkpoint inhibitors with radiotherapy and locoregional treatment : synergism and potential clinical implications 140
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 138
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 134
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer : a systematic review of randomized controlled trials 132
Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer 132
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 130
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 129
Immune approaches to the treatment of breast cancer, around the corner? 129
Best management of locally advanced inoperable breast cancer 129
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 129
RNAi screens identify CHD4 as an essential gene in breast cancer growth 127
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors : a Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group : Part 1 : Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 127
Adjuvant treatment of early male breast cancer 127
Immune checkpoint blockade in cancer treatment : a double-edged sword cross-targeting the host as an "innocent bystander" 126
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 125
Highlights from the 13th St Gallen International Breast Cancer Conference 2013 : access to innovation for patients with breast cancer: How to speed it up? 124
Impact of autoimmune diseases on outcome of patients with early breast cancer 123
Locoregional recurrence in patients with HER2 positive breast cancer 121
No link between breast cancer and meningioma : results from a large monoinstitutional retrospective analysis 121
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 119
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 119
Targeting fibroblast growth factor receptor pathway in breast cancer 118
Biopsy confirmation of metastatic sites in breast cancer patients : clinical impact and future perspectives 118
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus 118
Evolution of low HER2 expression between early and advanced-stage breast cancer 118
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study 117
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials 117
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 116
Metaplastic breast cancer: an all-round multidisciplinary consensus 115
Cardiotoxicity of anticancer treatments : epidemiology, detection, and management 115
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer : a retrospective multicenter study 115
Breast conservation following neoadjuvant therapy for breast cancer in the modern era : are we losing the opportunity? 114
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 114
Future potential targets of antibody-drug conjugates in breast cancer 113
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 109
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 108
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 107
Neoadjuvant model for testing emerging targeted therapies in breast cancer 107
Peptide vaccines in early breast cancer 106
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 104
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 104
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. 103
Successes and limitations of targeted cancer therapy in breast cancer 103
WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells 102
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer 101
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 100
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 99
Molecular pathways : human leukocyte antigen G(HLA-G) 97
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care 94
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO 92
HER2-Low Breast Cancer: a New Subtype? 90
Targeting brain metastases in breast cancer 90
Characterization of low HER2 expressions in de-novo metastatic breast cancer 88
Strategies to modulate the immune system in breast cancer : checkpoint inhibitors and beyond 88
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials 86
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer 84
Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer 84
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 84
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 83
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 83
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 83
Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? 81
Trop-2 as an Actionable Biomarker in Breast Cancer 79
Breast Cancer Genetics: Diagnostics and Treatment 79
Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours 79
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting 78
Crosstalk between bone niche and immune system : osteoimmunology signaling as a potential target for cancer treatment 77
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer 77
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 76
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 76
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 75
Cancer immunotherapy: tools and strategies to unmask a master of disguise 74
Mechanism of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist 74
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 74
Dinaciclib for the treatment of breast cancer 72
HER2 signaling pathway and trastuzumab cardiotoxicity 72
Tumor-stroma crosstalk : targeting stroma in breast cancer 71
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 70
Totale 15.480
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.583
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.583
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020390 0 0 0 0 0 0 0 0 0 189 110 91
2020/20211.867 115 119 135 93 279 126 109 144 209 156 184 198
2021/20221.529 140 136 96 97 137 96 148 75 212 106 62 224
2022/20231.646 181 155 178 155 129 267 63 122 186 41 111 58
2023/20244.057 111 152 101 180 319 252 557 466 258 466 582 613
2024/20253.793 525 557 478 532 377 239 180 584 316 5 0 0
Totale 17.411